Michael Barbella, Managing Editor11.07.22
Venus Concept Inc. has appointed Hemanth Varghese, Ph.D., as president and chief business officer.
“We are delighted to have Hemanth join Venus Concept at this pivotal time for the company,” Board Director and CEO Rajiv De Silva said. “Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and internationally, managing complex business transformations and high-growth corporate strategy initiatives, executing transformational M&A and driving critical business development activities. I believe Hemanth will bring an important, complementary skillset to our leadership team as we navigate the next phase of development for Venus Concept.”
Before joining Venus Concept Dr. Varghese was senior vice president of Strategy & Operations at HLS Therapeutics from 2017 to 2022. He previously worked for Endo International Plc, a multinational healthcare company, from 2014 to 2017 as president of International Pharmaceuticals and executive vice president of Corporate Development & Strategy. From 2009 to 2014, Dr. Varghese served as general manager of Vision Care at Bausch & Lomb and senior vice president of Corporate Development at Valeant Pharmaceuticals (now Bausch Health). He has also held leadership roles in venture capital and corporate development enterprises with a specialization in healthcare technology, medical devices and imaging modalities.
Dr. Varghese has an Honors BSc and a PhD in medical biophysics from Western University and is a CFA charterholder.
“I am honored to join Rajiv and the leadership team at Venus Concept at such an important time,” said Dr. Varghese. “Venus Concept has built a strong brand reputation and loyal following among aesthetic professionals, with a comprehensive portfolio of minimally invasive and non-invasive medical aesthetics technology solutions, an innovative R&D platform and a flexible commercial model delivering safe and effective aesthetic treatment options to consumers worldwide. I look forward to working with Rajiv and the leadership team to drive financial and operational performance, in order to take the enterprise to the next level and enhance long-term shareholder value creation.”
Venus Concept is a global medical aesthetic technology firm with a product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in more than 60 countries and 18 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems include NeoGraft and the ARTAS and ARTAS iX Robotic Hair Restoration systems. Venus Concept has been backed by healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
“We are delighted to have Hemanth join Venus Concept at this pivotal time for the company,” Board Director and CEO Rajiv De Silva said. “Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and internationally, managing complex business transformations and high-growth corporate strategy initiatives, executing transformational M&A and driving critical business development activities. I believe Hemanth will bring an important, complementary skillset to our leadership team as we navigate the next phase of development for Venus Concept.”
Before joining Venus Concept Dr. Varghese was senior vice president of Strategy & Operations at HLS Therapeutics from 2017 to 2022. He previously worked for Endo International Plc, a multinational healthcare company, from 2014 to 2017 as president of International Pharmaceuticals and executive vice president of Corporate Development & Strategy. From 2009 to 2014, Dr. Varghese served as general manager of Vision Care at Bausch & Lomb and senior vice president of Corporate Development at Valeant Pharmaceuticals (now Bausch Health). He has also held leadership roles in venture capital and corporate development enterprises with a specialization in healthcare technology, medical devices and imaging modalities.
Dr. Varghese has an Honors BSc and a PhD in medical biophysics from Western University and is a CFA charterholder.
“I am honored to join Rajiv and the leadership team at Venus Concept at such an important time,” said Dr. Varghese. “Venus Concept has built a strong brand reputation and loyal following among aesthetic professionals, with a comprehensive portfolio of minimally invasive and non-invasive medical aesthetics technology solutions, an innovative R&D platform and a flexible commercial model delivering safe and effective aesthetic treatment options to consumers worldwide. I look forward to working with Rajiv and the leadership team to drive financial and operational performance, in order to take the enterprise to the next level and enhance long-term shareholder value creation.”
Venus Concept is a global medical aesthetic technology firm with a product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in more than 60 countries and 18 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems include NeoGraft and the ARTAS and ARTAS iX Robotic Hair Restoration systems. Venus Concept has been backed by healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.